IPO Year: 2020
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/3/2025 | $23.00 | Strong Buy | Raymond James |
| 7/23/2025 | $3.00 | Neutral | Piper Sandler |
| 5/7/2025 | $20.00 | Outperform | Leerink Partners |
| 4/8/2025 | Outperform | William Blair |
Fastest customizable press release news feed in the world
PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference. The formal presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience. Details: Type: Company PresentationSpeakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical OfficerDate: Thursday, June 5th, 2025Time: 03:00 pm ETLocation: Webcast Follow
PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate at an upcoming Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum. Details: Type: Fireside ChatSpeakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical OfficerDate: Tuesday, May 27th, 2025Time: 08:00 am ETLocation: Webcast Following the event, a replay will be hosted on Kalaris Therapeutics' Investor Relations webpage. About Kalaris Kalaris is a clinical-stage
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Raymond James initiated coverage of Kalaris Therapeutics with a rating of Strong Buy and set a new price target of $23.00
Piper Sandler resumed coverage of Kalaris Therapeutics with a rating of Neutral and set a new price target of $3.00
Leerink Partners initiated coverage of Kalaris Therapeutics with a rating of Outperform and set a new price target of $20.00
William Blair initiated coverage of Kalaris Therapeutics with a rating of Outperform
10-Q - Kalaris Therapeutics, Inc. (0001754068) (Filer)
8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
DEFA14A - Kalaris Therapeutics, Inc. (0001754068) (Filer)
DEF 14A - Kalaris Therapeutics, Inc. (0001754068) (Filer)
8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
S-8 - Kalaris Therapeutics, Inc. (0001754068) (Filer)
SCHEDULE 13G/A - Kalaris Therapeutics, Inc. (0001754068) (Subject)
10-Q - Kalaris Therapeutics, Inc. (0001754068) (Filer)
8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)